Why Your GLP-1 Package Arrived Without a Prescription Label

Your GLP-1 package arrived. You opened it. The outer box has a shipping label with a pharmacy address. Inside, there's a vial, some syringes, and alcohol pads. But the vial itself has no prescription label. Just a lot number, maybe a drug name, maybe an expiration date. Where's the prescription?

The answer turns out to be a small regulatory story about how compounded drugs are labeled, what federal law actually requires, and when the missing label is fine versus when it's a serious problem. Here's what to check.

What federal law requires on a prescription label

For dispensed prescription drugs, the FDA and the Drug Quality and Security Act require labeling that includes:

• Name of the patient
• Name of the prescribing clinician
• Date of dispensing
• Prescription number
• Directions for use
• Name of the drug / active ingredient
• Strength
• Pharmacy name and address
• Lot number (for compounded drugs)
• Beyond-use date (for compounded drugs, equivalent of expiration)

State pharmacy laws may add additional requirements (most do). A compliant compounded GLP-1 vial should have all of this, either on the vial itself or on the accompanying paperwork.

Where the label can legitimately be

Three legitimate patterns for compounded GLP-1 labeling:

Pattern 1: Full label on the vial

Ideal. The vial itself has a pharmacy-printed label with patient name, clinician, drug, strength, directions. You can read everything you need from the vial alone. This is how major 503B facilities label.

Pattern 2: Full label on an accompanying sticker sheet

Common. The vial itself has a minimal printed label (drug name, lot, BUD). The full patient-specific labeling is on a separate sheet in the box — or on a peel-off sticker that's meant to be applied to the vial. This is compliant in most jurisdictions but requires that the sticker actually be in the package.

Pattern 3: Full label on the outer shipping paperwork

Less common but acceptable in some states. The vial has minimal labeling; the full pharmacy paperwork includes all patient-specific information. Less ideal because the vial is what survives in your fridge and the paperwork may get thrown away.

When "no label" is a real problem

• No patient name anywhere. If there's no paperwork with your name on it, federal dispensing requirements are not being met. This is a regulatory issue.
• No pharmacy name anywhere. You should be able to identify the source pharmacy. If you can't, the package may not be from a legitimately compounded source.
• No lot number. Lot numbers are required for recall tracking. Missing lot number means if there's a recall, you won't know whether your vial was affected.
• No beyond-use date. Compounded sterile products have short BUDs — typically 14–90 days depending on formulation. Without a BUD you have no way to know if the product is still in-date.
• No drug name or strength. You can't inject something safely if you don't know what it is or at what concentration.

The counterfeit/imported vial tell

A specific subcategory of "no label" is a vial that looks like it came from an API manufacturer rather than a U.S. compounding pharmacy. Telltales:

• Text in Chinese, Russian, or Indian English on the vial.
• A logo from an overseas chemical supplier.
• Measurements in units or formats not standard in U.S. pharmacy (e.g., dose stated in mg/mL without volume).
• Missing sterile packaging indicators (tamper-evident caps, sterility statement).
• A bare vial with no paperwork at all.

These patterns are consistent with research-grade peptides or gray-market imports rather than compounded U.S. pharmacy products. Injecting these is genuinely dangerous — sterility can't be verified, content can't be verified, and any adverse reaction has no recourse.

What to do in each scenario

Scenario 1: Missing paperwork but vial looks legitimate

1. Contact the platform's support. Request the full prescription paperwork by email.
2. Request the pharmacy's contact info and call them directly to confirm the lot.
3. Confirm the BUD with the pharmacy before injecting.
4. Don't inject until you have the missing information.

Scenario 2: Bare vial with no U.S. pharmacy markings

1. Don't inject.
2. Document (photograph) the vial, the packaging, and any paperwork.
3. Report to the FDA via MedWatch.
4. Request a full refund via credit card chargeback, not just through the platform.
5. Report to your state attorney general.

Scenario 3: Vial with minimal label, sticker sheet in box

1. Apply the sticker to the vial per instructions.
2. Verify all required information matches (your name, drug name, strength, BUD).
3. This is normal.

The sterility question

Even on a legitimately labeled vial, injectable compounded products are inherently higher-risk than brand-name pens. A compounded sterile product is only as sterile as the pharmacy's sterile compounding practice — documented via USP 797 compliance, sterility testing, and endotoxin testing. The best 503A pharmacies third-party test every batch. The worst skip this.

Tells for good sterile practice:

• Pharmacy publishes certificate of analysis for its GLP-1 batches (rare, excellent sign).
• Beyond-use date is short (14–90 days, consistent with USP 797 standards for sterile compounded products stored under specific conditions).
• Pharmacy has an unblemished state inspection record (public via state board).

When to escalate

A single labeling discrepancy on one shipment is often a shipping error that support can resolve. Repeated labeling issues across multiple shipments is an operational quality issue — the pharmacy isn't consistently following its own procedures, which is worrying for the things you can't see (sterility, potency).

If your pharmacy has labeling issues three shipments in a row, change pharmacies. If your platform refuses to tell you the pharmacy name or refuses to switch, change platforms.